Literature DB >> 27093686

Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings.

Brett W Sperry1, Michael N Vranian2, Rory Hachamovitch2, Hariom Joshi3, Meghann McCarthy3, Asad Ikram2, Mazen Hanna2.   

Abstract

BACKGROUND: Low voltage electrocardiography (ECG) coupled with increased ventricular wall thickness is the hallmark of cardiac amyloidosis. However, patient characteristics influencing voltage in the general population, including bundle branch block, have not been evaluated in amyloid heart disease.
METHODS: A retrospective analysis was performed of patients with newly diagnosed cardiac amyloidosis from 2002 to 2014. ECG voltage was calculated using limb (sum of QRS complex in leads I, II and III) and precordial (Sokolow: S in V1 plus R in V5-V6) criteria. The associations between voltage and clinical variables were tested using multivariable linear regression. A Cox model assessed the association of voltage with mortality.
RESULTS: In 389 subjects (transthyretin ATTR 186, light chain AL 203), 30% had conduction delay (QRS >120ms). In those with narrow QRS, 68% met low limb, 72% low Sokolow and 57% both criteria, with lower voltages found in AL vs ATTR. LV mass index as well as other typical factors that impact voltage (age, sex, race, hypertension, BSA, and smoking) in the general population were not associated with voltage in this cardiac amyloidosis cohort. Patients with LBBB and IVCD had similar voltages when compared to those with narrow QRS. Voltage was significantly associated with mortality (p<0.001 for both criteria) after multivariable adjustment.
CONCLUSION: Classic predictors of ECG voltage in the general population are not valid in cardiac amyloidosis. In this cohort, the prevalence estimates of ventricular conduction delay and low voltage are higher than previously reported. Voltage predicts mortality after multivariable adjustment.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bundle branch block; Cardiac amyloidosis; Electrocardiography; Infiltrative cardiomyopathy; Voltage

Mesh:

Year:  2016        PMID: 27093686     DOI: 10.1016/j.ijcard.2016.04.030

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  17 in total

Review 1.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

Review 2.  Hypertrophic cardiomyopathy: an updated review on diagnosis, prognosis, and treatment.

Authors:  George Makavos; Chris Κairis; Maria-Eirini Tselegkidi; Theodoros Karamitsos; Angelos G Rigopoulos; Michel Noutsias; Ignatios Ikonomidis
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

3.  Amyloid Cardiopathy and Aortic Stenosis.

Authors:  Leonida Gherasim
Journal:  Maedica (Bucur)       Date:  2021-09

4.  Clinical Implications of the Amyloidogenic V122I Transthyretin Variant in the General Population.

Authors:  Julia Kozlitina; Sonia Garg; Mark H Drazner; Susan A Matulevicius; Colby Ayers; John Overton; Jeffrey Reid; Aris Baras; Krishnasree Rao; Ambarish Pandey; Jarett Berry; James A de Lemos; Justin L Grodin
Journal:  J Card Fail       Date:  2021-10-09       Impact factor: 5.712

Review 5.  Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis.

Authors:  Perryn Lin Fei Ng; Yoke Ching Lim; Lauren Kay Mance Evangelista; Raymond Ching Chiew Wong; Ping Chai; Ching Hui Sia; Hoi Yin Loi; Tiong Cheng Yeo; Weiqin Lin
Journal:  Ann Noninvasive Electrocardiol       Date:  2022-05-14       Impact factor: 1.485

6.  Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis.

Authors:  Brett W Sperry; Matthew H Gonzalez; Richard Brunken; Manuel D Cerqueira; Mazen Hanna; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2018-01-17       Impact factor: 5.952

7.  Artificial intelligence-enabled fully automated detection of cardiac amyloidosis using electrocardiograms and echocardiograms.

Authors:  Shinichi Goto; Keitaro Mahara; Lauren Beussink-Nelson; Hidehiko Ikura; Yoshinori Katsumata; Jin Endo; Hanna K Gaggin; Sanjiv J Shah; Yuji Itabashi; Calum A MacRae; Rahul C Deo
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

Review 8.  Transthyretin cardiac amyloidosis: an update on diagnosis and treatment.

Authors:  Hiroyuki Yamamoto; Tomoki Yokochi
Journal:  ESC Heart Fail       Date:  2019-09-25

9.  Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis.

Authors:  Temidayo Abe; Eric Y Chang; Gabrielle De Allie; Taiwo Ajose; Chukwuemeka Nwokike; Nicolas Bakinde
Journal:  SAGE Open Med Case Rep       Date:  2020-05-20

10.  Noninvasive Mapping of the Electrophysiological Substrate in Cardiac Amyloidosis and Its Relationship to Structural Abnormalities.

Authors:  Michele Orini; Adam J Graham; Ana Martinez-Naharro; Christopher M Andrews; Antonio de Marvao; Ben Statton; Stuart A Cook; Declan P O'Regan; Philip N Hawkins; Yoram Rudy; Marianna Fontana; Pier D Lambiase
Journal:  J Am Heart Assoc       Date:  2019-09-08       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.